Neural Cells for Neurodegenerative Diseases in Clinical Trials

Stem Cells Transl Med. 2023 Aug 16;12(8):510-526. doi: 10.1093/stcltm/szad041.

Abstract

Neurodegenerative diseases (ND) are an entire spectrum of clinical conditions that affect the central and peripheral nervous system. There is no cure currently, with treatment focusing mainly on slowing down progression or symptomatic relief. Cellular therapies with various cell types from different sources are being conducted as clinical trials for several ND diseases. They include neural, mesenchymal and hemopoietic stem cells, and neural cells derived from embryonic stem cells and induced pluripotent stem cells. In this review, we present the list of cellular therapies for ND comprising 33 trials that used neural stem progenitors, 8 that used differentiated neural cells ,and 109 trials that involved non-neural cells in the 7 ND. Encouraging results have been shown in a few early-phase clinical trials that require further investigations in a randomized setting. However, such definitive trials may not be possible given the relative cost of the trials, and in the setting of rare diseases.

Keywords: Parkinson’s; cell therapy; clinical trials; neural stem cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Embryonic Stem Cells
  • Humans
  • Neurodegenerative Diseases* / therapy
  • Neurons / physiology
  • Pluripotent Stem Cells* / physiology
  • Stem Cell Transplantation / methods